BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

BACKGROUND: BEECH investigated the efficacy of capivasertib (AZD5363), an oral inhibitor of AKT isoforms 1–3, in combination with the first-line weekly paclitaxel for advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, N C, Alarcón, E, Armstrong, A C, Philco, M, López Chuken, Y A, Sablin, M -P, Tamura, K, Gómez Villanueva, A, Pérez-Fidalgo, J A, Cheung, S Y A, Corcoran, C, Cullberg, M, Davies, B R, de Bruin, E C, Foxley, A, Lindemann, J P O, Maudsley, R, Moschetta, M, Outhwaite, E, Pass, M, Rugman, P, Schiavon, G, Oliveira, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551452/
https://www.ncbi.nlm.nih.gov/pubmed/30860570
http://dx.doi.org/10.1093/annonc/mdz086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551452/
https://www.ncbi.nlm.nih.gov/pubmed/30860570
http://dx.doi.org/10.1093/annonc/mdz086

Ejemplares similares